Brukinsa was Designed to Completely Shut Off BTK

Brukinsa stays on, so BTK stays offBrukinsa stays on, so BTK stays off

Designed to optimize bioavailability, half-life, and selectivity to meet the challenges of BTK inhibition

1

Potent and sustained inhibition

100%, 24-hour inhibition of BTK in PBMCs*1,2

2

Target tissue exposure at therapeutic concentrations

Reaches and occupies BTK in plasma and lymph nodes1,2

3

High affinity for BTK

Minimal off-target binding to other tyrosine kinases including EGFR, FGR, FRK, HER2, HER4, ITK, JAK3, LCK, and TEC3

*The clinical significance of 100% occupancy has not been established.

BTK=Bruton's tyrosine kinase; PBMCs=peripheral blood mononuclear cells.

Powerful And
Sustained Responses

Efficacy

Demonstrated
Safety Profile

Safety
myBeiGene

Personalized Patient
Support Program

Patient Support